Patients
VKH disease, late-phase disease
DISEASE
Between 23 February 2021 and 28 October 2021, a total of 133 patients were screened, and 27 eligible patients with early-phase VKH disease and 83 with late-phase disease underwent stratified randomization (intention-to-treat population), with disease phase as a stratification factor. Of these participants, 56 were assigned to the immunosuppressant group with oral cyclosporine and 54 to the biologic group with adalimumab injection. In this pragmatic trial, 79 patients were included in the per-protocol population (Fig. 